Stryker Corp (SYK)
Fair ValueFundamental
74
Price
$275.39
Market Cap
$105.60B
Part 1 · What the company is worth
Overview
Stryker Corporation operates as a medical technology company in the United States and internationally. It operates through two segments, MedSurg and Neurotechnology, and Orthopaedics. The MedSurg and Neurotechnology segment offers surgical equipment, patient and caregiver safety technologies, navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, clinical communication and artificial intelligence-assisted virtual care platform technology, and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke and venous thromboembolism; traditional brain and open skull based surgical procedures products; and orthobiologic and biosurgery products, including synthetic bone grafts and vertebral augmentation products. The Orthopaedics segment provides implants for use in total joint replacements, such as hip, knee and shoulder, ankle, and trauma and extremities surgeries; and Mako Shoulder, which expands the smart robotics suite of applications. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 61 countries. Stryker Corporation was founded in 1941 and is headquartered in Portage, Michigan.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Balance Sheet & Liquidity
Revenue
$25.84B
Trailing 12 months (through 6/30/2026)
Net Income
$3.73B
Trailing 12 months (through 6/30/2026)
Free Cash Flow
$4.28B
Total Equity
$22.42B
Total Liabilities
$25.42B
Current Ratio
2.16
Interest Coverage
8.05
Debt/EBITDA
2.43
Earnings Per Share
Revenue & Net Income
Free Cash Flow
Income Breakdown
Historical statement
Margins over time
Debt over time
How heavy the debt is
Growth grid
Growth — Revenue
Fair Value Estimation
Fair Value
$291.11
Current Price
$275.39
Margin of Safety
+5.4%
Fair Value Range
$193.37 - $388.85
Spread across the valuation methods used, not a statistically calibrated confidence interval.
Estimation Methods
Valuation Metrics
P/E Ratio
28.54
ROE
14.5%
P/B Ratio
4.40
P/FCF
22.47
Gross Margin
65.0%
ROIC
9.6%
Profitability Radar
Value Creation (Economic Moat)
ROIC
9.6%
WACC
8.1%
ROIC − WACC
+1.5 pp
ROIC exceeds the cost of capital — the company is creating value for shareholders.
Fundamental Analysis Criteria
Passed (22)
- EPS shows upward trend
- EPS CAGR 7.11%
- Price CAGR 8.69%
- ROIC 9.6%
- Gross Margin 65.0%
- P/FCF 22.47
- Debt/Equity ratio
- Operating Margin 19.5%
- Positive Free Cash Flow
- CapEx intensity
- Current Ratio
- Interest Coverage
- Debt/EBITDA
- Return on Tangible Assets
- ROE 16.4%
- Revenue Growth 5Y 11.8%
- Analyst Consensus 79% Buy
- PEG Ratio 1.91
- Earnings Quality (OCF/NI) 1.48
- Share Dilution 0.2%
- Net Margin Trend 14.4% vs 12.3%
- Piotroski F-Score 5/9
Failed (5)
- P/B Ratio 4.40
- Low reliance on intangibles
- Price below Graham Number
- DCF valuation (Overvalued)
- Earnings Surprise avg -1.9%
Unavailable (1)
- Dividend Payout NaN%
Piotroski F-Score
Mixed signals: some areas need attention
Earnings Quality
High quality: earnings backed by cash
Share Dilution
Share count is stable
Institutional Holdings
Governance
Executive Team
| Name | Title | Age |
|---|---|---|
| Mr. Kevin A. Lobo | Chairman & CEO | 60 |
| Mr. Spencer S. Stiles | President & COO | 48 |
| Mr. Preston W. Wells | VP & CFO | 48 |
| Mr. Viju S. Menon | Group President of Global Quality & Operations | 57 |
| Mr. J. Andrew Pierce | Group President of MedSurg & Neurotechnology | 51 |
| Ms. Emily Baculik | VP, Chief Accounting Officer & Corporate Controller | 45 |
| Mr. Robert C. Cohen | CTO and VP of Global R&D - Joint Replacement | - |
| Ms. Debra S. King | VP and Chief Digital & Information Officer | 53 |
| Mr. Nick Mead | Vice President of Investor Relations | - |
| Mr. Robert S. Fletcher | VP & Chief Legal Officer | 54 |
Audit Risk
10
Board Risk
9
Compensation Risk
1
Shareholder Rights Risk
6
Part 2 · The price and when to enter
This part won't tell you whether the company is worth owning: it helps you choose when to buy it, once the fundamentals have convinced you. Inside: technical analysis, potential, historical drawdowns, gamma exposure.
Documents
- View document
Annual Report (10-K)
A yearly overview of the business, its financial results, and the risks it faces.
Filed on 2026-02-11
- View document
Quarterly Report (10-Q)
A snapshot of financial performance for the most recent three-month period.
Filed on 2026-07-31
- View document
Current Report (8-K)
An announcement of a major event, such as a leadership change or big news.
Filed on 2026-07-30
via SEC EDGAR
Income History
via SEC EDGAR
Latest News
Recent headlines for SYK, sourced from Markets Gazette.